Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
Cytokinetics (CYTK) Stock Price & Analysis
645 Followers
CYTK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$32.96 - $55.80
Previous Close$37.36
Volume371.63K
Average Volume (3M)994.45K
Market Cap
$3.57B
Enterprise Value$3.11B
Total Cash (Recent Filing)$663.96M
Total Debt (Recent Filing)$203.71M
Price to Earnings (P/E)-8.2
Beta0.94
Next Earnings
Aug 10, 2023EPS Estimate
-$1.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.58
Shares Outstanding95,640,600
10 Day Avg. Volume652,222
30 Day Avg. Volume994,450
Standard Deviation0.16
R-Squared0.07
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)-15.68
Price to Sales (P/S)774.58
Price to Cash Flow (P/CF)-7.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue31.75
Enterprise Value/Gross Profit32.91
Enterprise Value/Ebitda-8.06
Forecast
1Y Price Target
$59.08Price Target Upside58.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Cytokinetics News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CYTK FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $32.96 and its highest was $55.80 in the past 12 months.
What is Cytokinetics’s market cap?
Currently, no data Available
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Aug 10, 2023 which is in 72 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on May 04, 2023. The company reported -$1.38 earnings per share for the quarter, missing the consensus estimate of -$1.203 by -$0.177.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -$1.14.
How many shares outstanding does Cytokinetics have?
Cytokinetics has 95,640,600 shares outstanding.
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$1.38 in its last earnings report, missing expectations of -$1.203. Following the earnings report the stock price went up 0.382%.
Which hedge fund is a major shareholder of Cytokinetics?
Among the largest hedge funds holding Cytokinetics’s share is Farallon Capital Management, L.L.C.. It holds Cytokinetics’s shares valued at 33M.
---
Cytokinetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$59.08 (58.14% Upside)
$59.08 (58.14% Upside)
Blogger Sentiment
Bullish
CYTK Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 929.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.92%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cytokinetics
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.
---
Top 5 ETFs holding CYTK
Vanguard Health Care ETF
$11.76M
iShares Core S&P Total U.S. Stock Market ETF
$3.63M
Schwab U.S. Broad Market ETF
$1.89M
Fidelity MSCI Health Care Index ETF
$1.80M
iShares NASDAQ US Biotechnology UCITS ETF
$1.70M
Up to five ETFs with an Outperform Smart Score that hold CYTK. The ETFs are listed according to market value of CYTK within the ETF
---
Cerevel Therapeutics Holdings
―
Denali Therapeutics
―
Natera
―
Intellia Therapeutics
―
---